started · updated
Mantecorp launches Semavy weight-loss pen in Brazil
Mantecorp has announced the launch of Semavy, a semaglutide-based weight loss pen, which is now being distributed in pharmacies across Brazil. Approved by Anvisa, the medication aims to provide a more accessible option for weight management and metabolic health.
Medical experts note that while GLP-1 analog medications are effective at reducing appetite and delaying gastric emptying, rapid weight loss can lead to secondary effects. Research indicates that sudden loss of subcutaneous fat may cause skin sagging and loss of facial contour, often requiring aesthetic interventions like collagen biostimulators to maintain skin firmness.
Additionally, some users report sensory changes, such as a decreased interest in sweets or a sudden aversion to sweet fragrances like vanilla and chocolate. Specialists suggest this is likely due to the medication's impact on the brain's reward system and taste perception rather than a direct change in the sense of smell.
Entities
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Rapid weight loss from GLP-1 medications can cause skin sagging and loss of facial structural support. www.incorporeestetica.com.br
- [○ 1 SOURCE] GLP-1 analog studies show these medications reduce appetite and delay gastric emptying to aid weight loss. www.incorporeestetica.com.br
- [○ 1 SOURCE] Users may experience changes in sensory perception, such as discomfort with sweet scents, due to altered taste and reward system responses. delas.ig.com.br
- [○ 1 SOURCE] The Semavy medication has received approval from Anvisa. portalleodias.com
- [○ 1 SOURCE] Mantecorp has launched Semavy, a semaglutide weight-loss pen, for distribution in Brazilian pharmacies. portalleodias.com